• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验

Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.

作者信息

Howard Sarah, Scott Ian A, Ju Hong, McQueen Liam, Scuffham Paul A

机构信息

Healthcare Evaluation and Assessment of Technology, Healthcare Improvement Unit, Clinical Excellence Division, Queensland Department of Health, Level 2, 15 Butterfield Street, Herston, Qld 4006, Australia. Email.

Department of Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Qld 4102, Australia. Email.

出版信息

Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.

DOI:10.1071/AH18042
PMID:30205873
Abstract

Objectives In determining whether new health technologies should be funded, health technology assessment (HTA) committees prefer explicit to implicit methods of analysis in enhancing transparency and consistency of decision making. The aim of this study was to develop and pilot a multicriteria decision analysis (MCDA) framework for the Queensland Department of Health HTA program committee, which weighted decision making criteria according to their perceived importance as determined by group consensus. Methods The criteria used in the MCDA framework were identified by reviewing the five unweighted criteria used in the existing process, consultation with committee members and literature review. Criteria were clearly defined and ordinal categories of lowest to highest preferred were assigned against which technology submissions would be rated. Criteria weights were determined through a discrete choice experiment (DCE) survey of committee members using validated software. Mean weighted technology scores were then used to guide deliberative discussions in determining final funding decisions. Results The MCDA framework created one additional criterion to the previous five. The criteria and their mean weights identified through the DCE survey were clinical benefit and safety (27.2%), quality of evidence (19.2%), implementation capacity (16.9%), innovation (15.4%), burden of disease and clinical need (13.3%) and societal and ethical values (8.0%). Criterion weights varied considerably between individual committee members, with one criterion having a difference of 36.9% between the highest and lowest preference weights. Following deliberative discussions, all but one of 10 submissions were awarded funding. The submission not supported received the third lowest score through the MCDA model. Conclusions This pilot application of an MCDA framework, as a complement to committee deliberation, conferred greater transparency and objectivity on HTA assessment of technologies. The framework converted an implicit, unweighted review process to one that is more explicit, flexible in weighting importance and pragmatic. What is known about the topic? HTA programs involve complex decision-making processes requiring the consideration of multiple criteria. Explicit methods of analysis that use weighted criteria according to their relative importance enhance transparency and consistency of decision making by HTA committees, and are preferred to implicit reviews using unweighted criteria. What does this paper add? This article describes the development and piloting of an MCDA framework that aims to improve transparency, objectivity and consistency of funding decisions of the Queensland HTA committee. Criteria were identified through a review of current processes, committee discussions and a literature review, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality of evidence system. Criteria were weighted using a discrete choice experiment involving committee members. Using weighted criteria, mean technology scores were calculated and incorporated into deliberative discussions to determine funding decisions. What are the implications for practitioners? The MCDA framework described here converted a more implicit, unweighted process to one that was more pragmatic, explicit and flexible in scoring HTA submissions. This framework may be useful to other HTA programs and could be expanded to resource allocation decision making in many other healthcare settings.

摘要

目标 在确定新的卫生技术是否应获得资金支持时,卫生技术评估(HTA)委员会在提高决策的透明度和一致性方面,更倾向于采用明确的分析方法而非隐含的方法。本研究的目的是为昆士兰卫生部HTA项目委员会开发并试行一个多标准决策分析(MCDA)框架,该框架根据委员会成员共同认定的重要性对决策标准进行加权。方法 通过回顾现有流程中使用的五个未加权标准、与委员会成员进行磋商以及文献综述,确定了MCDA框架中使用的标准。对标准进行了明确界定,并划分了从最低偏好到最高偏好的有序类别,据此对技术申报进行评分。通过使用经过验证的软件对委员会成员进行离散选择实验(DCE)调查来确定标准权重。然后,使用平均加权技术得分来指导审议讨论,以确定最终的资金决策。结果 MCDA框架在之前的五个标准基础上新增了一个标准。通过DCE调查确定的标准及其平均权重分别为临床效益与安全性(27.2%)、证据质量(19.2%)、实施能力(16.9%)、创新性(15.4%)、疾病负担与临床需求(13.3%)以及社会和伦理价值(8.0%)。各个委员会成员之间的标准权重差异很大,其中一个标准的最高偏好权重与最低偏好权重相差36.9%。经过审议讨论,10份申报中有9份获得了资金支持。未获支持的申报在MCDA模型中得分第三低。结论 作为委员会审议的补充,MCDA框架的此次试行应用使HTA技术评估具有了更高的透明度和客观性。该框架将一个隐含的、未加权的审查过程转变为一个更明确、在权重重要性方面更灵活且务实的过程。关于该主题已知的信息有哪些?HTA项目涉及复杂的决策过程,需要考虑多个标准。根据相对重要性使用加权标准的明确分析方法可提高HTA委员会决策的透明度和一致性,比使用未加权标准的隐含审查更受青睐。本文补充了哪些内容?本文描述了一个MCDA框架的开发和试行情况,该框架旨在提高昆士兰HTA委员会资金决策的透明度、客观性和一致性。通过回顾当前流程、委员会讨论和文献综述以及推荐分级评估、制定与评价(GRADE)证据质量系统来确定标准。通过涉及委员会成员的离散选择实验对标准进行加权。使用加权标准计算平均技术得分,并将其纳入审议讨论以确定资金决策。对从业者有何影响?此处描述的MCDA框架将一个更隐含、未加权的过程转变为一个在对HTA申报进行评分时更务实、明确且灵活的过程。该框架可能对其他HTA项目有用,并且可以扩展到许多其他医疗环境中的资源分配决策。

相似文献

1
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
2
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
3
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.将卫生技术评估 (HTA) 与多准则决策分析 (MCDA) 相结合:在加拿大,对公共支付方进行覆盖决策的 EVIDEM 框架进行现场测试。
BMC Health Serv Res. 2011 Nov 30;11:329. doi: 10.1186/1472-6963-11-329.
4
Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.南非宫颈癌筛查检测覆盖的多准则决策分析(MCDA)框架的现场测试。
Cost Eff Resour Alloc. 2012 Feb 29;10(1):2. doi: 10.1186/1478-7547-10-2.
5
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.多准则决策分析支持卫生技术评估机构:收益、限制和未来发展方向。
Value Health. 2019 Nov;22(11):1283-1288. doi: 10.1016/j.jval.2019.06.014. Epub 2019 Oct 16.
6
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.多准则决策分析在四个欧盟成员国的卫生技术评估中的应用:预价值框架的试点。
Soc Sci Med. 2020 Feb;246:112595. doi: 10.1016/j.socscimed.2019.112595. Epub 2019 Oct 15.
7
Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework.基于医院的卫生技术评估中评估癌症治疗方法的多准则决策分析(MCDA):矛盾价值框架。
PLoS One. 2022 May 25;17(5):e0268584. doi: 10.1371/journal.pone.0268584. eCollection 2022.
8
Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making.采用多准则决策分析制定儿科健康技术的价值评估框架:为资金决策拓宽价值视角。
Value Health. 2024 Jul;27(7):879-888. doi: 10.1016/j.jval.2024.03.012. Epub 2024 Mar 27.
9
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.避免和识别健康技术评估模型中的错误:定性研究和方法学综述。
Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250.
10
Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016.利用多标准决策分析(MCDA)支持医疗保健决策 FIFARMA,2016年
J Mark Access Health Policy. 2017 Oct 12;5(1):1360545. doi: 10.1080/20016689.2017.1360545. eCollection 2017.

引用本文的文献

1
Stakeholder survey about broad elements of value in health technology assessment in Australia: industry and academia more similar than different.关于澳大利亚卫生技术评估中广泛价值要素的利益相关者调查:行业与学术界的相似之处多于不同之处。
Int J Technol Assess Health Care. 2025 Jul 8;41(1):e61. doi: 10.1017/S0266462325100226.
2
Health technology assessment and innovation: here to help or hinder?卫生技术评估与创新:是帮手还是阻碍?
Int J Technol Assess Health Care. 2024 Oct 24;40(1):e37. doi: 10.1017/S026646232400059X.
3
Development of an multicriteria decision analysis framework for rare disease reimbursement prioritization in Malaysia.
马来西亚罕见病报销优先级排序的多准则决策分析框架的开发。
Int J Technol Assess Health Care. 2024 Sep 4;40(1):e35. doi: 10.1017/S026646232400031X.
4
Quantifying stakeholders' preference for implantable medical devices in China: a discrete choice experiment.定量中国医疗器械植入物利益相关者偏好的离散选择实验
Int J Technol Assess Health Care. 2024 Jan 15;40(1):e8. doi: 10.1017/S0266462323002799.
5
The role of Iran's context for the development of health technology assessment: challenges and solutions.伊朗背景在卫生技术评估发展中的作用:挑战与解决方案。
Health Econ Rev. 2023 Apr 20;13(1):23. doi: 10.1186/s13561-023-00438-7.
6
A Rapid Literature Review of Multi-Criteria Decision Support Methods in the Context of One Health for All-Hazards Threat Prioritization.多准则决策支持方法在全健康背景下用于所有危害威胁优先级排序的快速文献综述。
Front Public Health. 2022 Apr 15;10:861594. doi: 10.3389/fpubh.2022.861594. eCollection 2022.
7
Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain).药品早期准入:多标准决策分析(MCDA)在西班牙加泰罗尼亚作为决策工具的应用
J Clin Med. 2022 Mar 1;11(5):1353. doi: 10.3390/jcm11051353.
8
Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.支持中高收入国家创新药物评估的框架潜在标准——关于价值框架和多标准决策分析的系统文献综述
Front Pharmacol. 2020 Aug 14;11:1203. doi: 10.3389/fphar.2020.01203. eCollection 2020.
9
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.糖尿病性黄斑水肿管理中的多利益相关者多标准决策分析:MULTIDEX-EMD研究。
Pharmacoecon Open. 2020 Dec;4(4):615-624. doi: 10.1007/s41669-020-00201-2.